A novel administration route of edaravone - II: Mucosal absorption of edaravone from edaravone/hydroxypropyl-beta-cyclodextrin complex solution including L-cysteine and sodium hydrogen sulfite

Pharmacology

Volumn 85, Issue 2, 2010, Pages 88-94

  Sato, Toshiaki ^a   Mizuno, Keizo ^a   Ishii, Fumiyoshi ^a  

^a MEIJI PHARMACEUTICAL UNIVERSITY   (Japan)

Author keywords

Edaravone; Hydroxypropyl cyclodextrin; L Cysteine; Oral mucosal administration; Rectal administration; Sodium hydrogen sulfite

Indexed keywords

2 HYDROXYPROPYL BETA CYCLODEXTRIN; BISULFITE; CYSTEINE; NORPHENAZONE; 2-HYDROXYPROPYL-BETA-CYCLODEXTRIN; BETA CYCLODEXTRIN DERIVATIVE; HYDROGEN SULFITE; PHENAZONE; PHENYLMETHYLPYRAZOLONE; SODIUM SULFITE; SOLUTION AND SOLUBILITY; SULFITE;

ANESTHESIA; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ABSORPTION; DRUG ADMINISTRATION ROUTE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG FORMULATION; DRUG HALF LIFE; MALE; MAXIMUM PLASMA CONCENTRATION; MOUTH MUCOSA; NONHUMAN; PRIORITY JOURNAL; RAT; RECTUM MUCOSA; TIME TO MAXIMUM PLASMA CONCENTRATION; ABSORPTION; ADMINISTRATION AND DOSAGE; ANALOGS AND DERIVATIVES; ANIMAL; COMPARATIVE STUDY; DRUG EFFECTS; METABOLISM; ORAL DRUG ADMINISTRATION; PHARMACOKINETICS; PHYSIOLOGY; RECTAL DRUG ADMINISTRATION; RECTUM; SOLUTION AND SOLUBILITY; WISTAR RAT;

ABSORPTION; ADMINISTRATION, ORAL; ADMINISTRATION, RECTAL; ANIMALS; ANTIPYRINE; BETA-CYCLODEXTRINS; CYSTEINE; MALE; MOUTH MUCOSA; PHARMACEUTICAL SOLUTIONS; RATS; RATS, WISTAR; RECTUM; SULFITES;

EID: 75149119371     PISSN: 00317012     EISSN: None     Source Type: Journal    
DOI: 10.1159/000276548     Document Type: Article

References (28)

1. Houkin K, Nakayama N, Kamada K, Noujou T, Abe H, Kashiwaba T: Neuroprotective effect of the free radical scavenger MCI-186 in patients with cerebral infarction: clinical evaluation using magnetic resonance imaging and spectroscopy. J Stroke Cerebrovasc Dis 1998;7:315-322.
2. Kawai H, Nakai H, Suga M, Yuki S, Watanabe T, Saito KI: Effects of a novel free radical scavenger, MCI-186, on ischemic brain damage in the rat distal middle cerebral artery occlusion model. J Pharmacol Exp Ther 1997;281:921-927.
3. Yamamoto T, Yuki S, Watanabe T, Mitsuka M, Saito K: Delayed neuronal death prevented by inhibition of increased hydroxyl radical formation in a transient cerebral ischemia. Brain Res 1997; 762: 240-242.
4. Watanabe T, Morita I, Nishi H, Murota S: Preventive effect of MCI-186 on 15-HPETE induced vascular endothelial cell injury in vitro. Prostaglandins Leukot Essent Fatty Acids 1988;33:81-87.
5. Watanabe T, Yuki S, Egawa M, Nishi H: Protective effects of MCI-186 on cerebral ischemia: possible involvement of free radical scavenging and antioxidant actions. J Phamacol Exp Ther 1994;268:1597-1604.
6. Fukudome D, Matsuda M, Kawasaki T, Ago Y, Matsuda T: The radical scavenger edaravone counteracts diabetes in multiple low-dose streptozotocin-treated mice. Eur J Pharmacol 2008;583:164-169.
7. Araki Y, Andoh A, Fujiyama Y: The free radical scavenger edaravone suppresses experimental dextran sulfate sodium-induced colitis in rats. Int J Mol Med 2003;12:125-129.
8. Arii K, Kumon Y, Ikeda Y, Suehiro T, Hashimoto K: Edaravone inhibits rheumatoid synovial cell proliferation and migration. Free Radic Res 2006;40:121-125.
9. Arii K, Kumon Y, Ikeda Y, Suehiro T, Hashimoto K: Edaravone inhibits the activity in rheumatoid arthritis. J Clin Pharm Ther 2006;31:197-199.
10. Cimen MY, Cimen OB, Kacmaz M, Ozturk HS, Yorgancioglu R, Durak I: Oxidant/antioxidant status of the erythrocytes from patients with rheumatoid arthritis. Clin Rheumatol 2000;19:275-277.
11. Ozturk HS, Cimen MY, Cimen OB, Kacmaz M, Durak I: Oxidant/antioxidant status of plasma sample from patients with rheumatoid arthritis. Rheumatol Int 1999;19:35-37.
12. Mazzetti I, Grigolo B, Pulsatelli L, Pulsatelli L, Dolzani P, Silvestri T, Roseti L, Meliconni R, Facchini A: Differential roles of nitric oxide and oxygen radicals in chondrocytes affected by osteoarthritis and rheumatoid arthritis. Clin Sci (Lond) 2001;101:593-599.
13. Miesel R, Murphy MP, Kroger H: Enhanced mitochondrial radical production in patients with rheumatoid arthritis correlates with elevated levels of tumor necrosis factor alpha in plasma. Free Radic Res 1996;25:161-169.
14. Yoshino H, Kimura A: Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (phase II study). Amyotroph Lateral Scler 2006;7:241-245.
15. Sato T, Mizuno K, Ishii F: Effects of various cyclodextrine on solubility and penetration through the synthesized membrane of edaravone. Mater Technol 2005;23:403-408.
16. Sato T, Mizuno K, Ishii F: Effects of hydroxypropyl-β-cyclodextrin on the transdermal delivery of edaravone through hairless rat skin. Mater Technol 2006; 24: 79-84.
17. Sato T, Mizuno K, Ishii F: In vitro metabolism study of edaravone in Wistar and hair-less rat skin. Biol Pharm Bull 2008;31:1150-1154.
18. Adrian CL, Olin HB, Dalhoff K, Jacobsen J: In vivo human buccal permeability of nicotine. Int J Pharm 2006;311:196-202.
19. Jensen KM, Mikkelsen S: Studies on the bioavailability of glyceryl trinitrate after sublingual administration of spray and tablet. Arzneimittelforschung 1997;47:716-718.
20. Okayama M, Tsubouchi R, Nishio H, Kato S, Takeuchi K: Protective effect of intra-rectal administration of rebamipide on dextran sulfate sodium-induced rat colitis. Digestion 2004;70:240-249.
21. Miyake M, Kamada N, Oka Y, Mukai T, Minami T, Toguchi H, Odomi M, Ogawara K, Higaki K, Kimura T: Development of suppository formulation safely improving rectal absorption of rebamipide, a poorly absorbable drug, by utilizing sodium laurate and taurine. J Control Rel 2004;99:63-71.
22. Komatsu T, Nakai H, Takamatsu Y, Morinaka Y, Watanabe K, Shinoda M, Iida S: Pharmacokinetic studies of 3-methyl-1-phenyl-2-pyrazolin-5-one (MCI-186): metabolism in rats, dog and human. Drug Metab Pharmacokinet 1996;11:451-462.
23. Seideman P, Ericsson O, Gröningsson K, von Bahr C: Effect of pentobarbital on the formation of diastereomeric oxazepam glucuronides in man: analysis by high performance liquid chromatography. Acta Pharmacol Toxicol 1981;49:200-204.
24. Dale BA, Salonen J, Jones AH: New approaches and concepts in the study of differentiation of oral epithelia. Crit Rev Oral Biol Med 1990;1:167-190.
25. Babu RJ, Kikwai L, Jaiani LT, Kanikkannan N, Armstrong CA, Ansel JC, Singh M: Percutaneous absorption and anti-inflammatory effect of a substance P receptor antagonist: spantide II. Pharm Res 2004;21:108-112.
26. Schauber J, Weiler F, Gostner A, Melcher R, Kudlich T, Lührs H, Scheppach W: Human rectal mucosal gene expression after consumption of digestible and non-digestible carbohydrates. Mol Nutr Food Res 2006;50:1006-1012.
27. Kanner J, Lapidot T: The stomach as a bioreactor: dietary lipid peroxidation in the gastric fluid and the effects of plant-derived antioxidants. Free Radic Biol Med 2001:31:1388-1395.
28. Watanabe T, Tanaka M, Watanabe K, Takamatsu Y, Tobe A: Research and development of the free radical scavenger edaravone as neuroprotectant. Yakugaku Zasshi 2004;124:99-111.